2021
DOI: 10.1016/j.ejso.2020.08.027
|View full text |Cite
|
Sign up to set email alerts
|

The cost-effectiveness of TheraSphere in patients with hepatocellular carcinoma who are eligible for transarterial embolization

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
49
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
7

Relationship

0
7

Authors

Journals

citations
Cited by 20 publications
(49 citation statements)
references
References 26 publications
0
49
0
Order By: Relevance
“…The present evaluation was based on a range of evidence including a Phase III European RCT, other published data and a resource use survey conducted in the UK. While the cost-effectiveness of SIRT using Y-90 glass microspheres has recently been explored in another, similar population, among patients with unresectable HCC who are eligible for TACE [44], this evaluation was based on a single-center retrospective study and is therefore at risk of bias. However, despite the use of Phase III RCT data, uncertainties remain in the present evaluation as with all economic evaluations.…”
Section: Discussionmentioning
confidence: 99%
“…The present evaluation was based on a range of evidence including a Phase III European RCT, other published data and a resource use survey conducted in the UK. While the cost-effectiveness of SIRT using Y-90 glass microspheres has recently been explored in another, similar population, among patients with unresectable HCC who are eligible for TACE [44], this evaluation was based on a single-center retrospective study and is therefore at risk of bias. However, despite the use of Phase III RCT data, uncertainties remain in the present evaluation as with all economic evaluations.…”
Section: Discussionmentioning
confidence: 99%
“…Four economic evaluations 20,[25][26][27] (including an independent economic analysis 20 conducted as part of the health technology assessment) were identified regarding the cost-effectiveness of 90 Y microspheres for the treatment of hepatocellular carcinoma. 30 The fourth economic evaluation by Rognoni et al (2017) 27 was a cohortbased multistate Markov model that had cycle lengths of 1 month.…”
Section: Methodsmentioning
confidence: 99%
“…These comprised 1 health technology assessment (which included a systematic review with network meta-analyses and an economic evaluation), 20 3 systematic reviews with meta-analyses, [21][22][23] 1 non-randomized study, 24 and 3 economic evaluations. [25][26][27] Appendix 1 presents the Prevention and Recovery Information System for Monitoring and Analysis (PRISMA) 28 flow chart of the study selection.…”
Section: Quantity Of Research Availablementioning
confidence: 99%
See 1 more Smart Citation
“…Controversially, a 2018 review comparing patients receiving SIRT, 3D-CRT and SBRT showed no significant difference in OS between them at 1 year [121], but appropriate patient selection would be a deciding factor for this parameter. A recent UK-based report by Manas et al evaluated the cost-effectiveness of TheraSphere against other embolic treatments such as conventional TACE (cTACE) or drug-eluting bead TACE (DEB-TACE) and found that for patients with early to intermediate HCC, treatment with TheraSphere is costeffective, mostly because of its more successful downstaging ability [122]. In another multicentric cohort study, while transplant-free survival was similar between SIRT and DEB-TACE, SIRT's effectiveness was observed even with significantly larger median tumor size [123].…”
Section: Radiolabeled Microparticlesmentioning
confidence: 99%